首页> 中文期刊> 《中国药物警戒》 >基于加权TOPSIS法的伏立康唑注射剂药物利用评价

基于加权TOPSIS法的伏立康唑注射剂药物利用评价

         

摘要

Objective To establish the evaluation standard for voriconazole injection based on weighted TOPSIS, and provide a reasonable basis for clinical application Methods The reasonable application evaluation system of voriconazole injection was established based on weighted TOPSIS with reference to the dispensatory and application guide of voriconzole, and 100 voriconazole injection utilizing cases that happened in the first half of 2017 in our hospital were evaluated. Results Among the 100 patients, there were 25 cases whose relative approach degree were larger than 80% (accounting for 25%), 37 cases whose relative approach degree were between 60%~80% (accounting for 37%), and 38 cases whose relative approach degree were below 60%(accounting for 38%). Conclusion The reasonable application evaluation system of voriconazole injection based on weighted TOPSIS methods can be used to evaluate the rationality of drug use and promote more rational evaluation behavior. The results showed that irrational administrations of voriconzole for injection are fairly common problems in our hospital, which means regulation should be strengthened.%目的探讨基于加权TOPSIS法的伏立康唑注射剂的药物利用评价方法,促进其合理应用.方法以伏立康唑注射剂药品说明书及国内外真菌治疗临床指南为依据,制定基于加权TOPSIS法的伏立康唑注射剂临床应用评价标准,并据此对我院2017年1-6月使用了伏立康唑注射剂的100份出院病历进行回顾性评价.结果使用了伏立康唑注射剂的100份病历中,相对接近度大于80%的有25例(占25%),相对接近度在60%~80%区间的有37例(占37%);相对接近度小于60%有38例(占38%).结论基于加权TOPSIS法制定的伏立康唑注射剂临床应用评价方法可以用于该药的用药合理性评价,评价结果显示我院伏立康唑注射剂临床应用中仍存在较多不合理用药情况,需进一步加强管控.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号